186 related articles for article (PubMed ID: 35903892)
21. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
[TBL] [Abstract][Full Text] [Related]
22. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer.
Köstek O; Yılmaz E; Hacıoğlu MB; Demircan NC; Gökyer A; Uzunoğlu S; Tunçbilek N; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Apr; 83(4):735-742. PubMed ID: 30680522
[TBL] [Abstract][Full Text] [Related]
23. Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report.
Nasso C; Sabbatini R; Baldessari C; Dominici M; Vitale MG
Tumori; 2021 Dec; 107(6):NP33-NP36. PubMed ID: 33526000
[TBL] [Abstract][Full Text] [Related]
24. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
[TBL] [Abstract][Full Text] [Related]
25. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
Cerbone L; Nunno VD; Carril Ajuria L; Alves Costa Silva C; Colomba E; Guida A; Salviat F; Hirsch L; Benchimol-Zouari A; Flippot R; Escudier B; Albiges L
Clin Genitourin Cancer; 2022 Feb; 20(1):80-87. PubMed ID: 34688544
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S; Goldman JM; Nazha B; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
Clin Genitourin Cancer; 2022 Feb; 20(1):53-59. PubMed ID: 34922840
[TBL] [Abstract][Full Text] [Related]
27. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy of cabozantinib in two pediatric patients with recurrent renal cell carcinoma.
Wedekind MF; Ranalli M; Shah N
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28417541
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
[TBL] [Abstract][Full Text] [Related]
30. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
31. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
32. Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Vano YA; Phan L; Gravis G; Korakis I; Schlürmann F; Maillet D; Bennamoun M; Houede N; Topart D; Borchiellini D; Barthelemy P; Ratta R; Ryckewaert T; Hasbini A; Hans S; Emambux S; Cournier S; Braychenko E; Elaidi RT; Oudard S
Int J Cancer; 2022 Oct; 151(8):1335-1344. PubMed ID: 35603906
[TBL] [Abstract][Full Text] [Related]
33. Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma.
Herrmann T; Mione C; Montoriol PF; Molnar I; Ginzac A; Durando X; Mahammedi H
Oncology; 2022; 100(2):114-123. PubMed ID: 34999587
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.
Motzer RJ; Escudier B; Powles T; Scheffold C; Choueiri TK
Br J Cancer; 2018 May; 118(9):1176-1178. PubMed ID: 29576624
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
36. Cabozantinib use in renal cell carcinoma.
Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW
Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002
[TBL] [Abstract][Full Text] [Related]
37. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
[TBL] [Abstract][Full Text] [Related]
38. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.
Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G
Clin Genitourin Cancer; 2019 Aug; 17(4):291-298. PubMed ID: 31178240
[TBL] [Abstract][Full Text] [Related]
39. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
Gross-Goupil M; Bodnar L; Campbell MT; Michael A; Venugopal B; Żołnierek J; Dutailly P; Procopio G; Albiges L
Clin Genitourin Cancer; 2024 Feb; 22(1):84-97. PubMed ID: 38101983
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
Mennitto A; Zattarin E; Di Maio M; Bimbatti D; De Giorgi U; Buti S; Santini D; Casadei C; Sorarù M; Messina C; Mucciarini C; Di Lorenzo G; Roviello G; Buttigliero C; Stellato M; Sepe P; Claps M; Guadalupi V; Ottini A; Pignata S; De Braud FG; Verzoni E; Procopio G
Expert Rev Anticancer Ther; 2022 Jan; 22(1):115-121. PubMed ID: 34738499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]